SPHK2 and glioblastoma: Furthermore, the treatment of mice with the selective SK2 inhibitor K145 reduced the subcutaneous tumor growth of U251 GBM cells, providing further evidence that targeting sphingolipid metabolism in GBM may be a viable therapeutic option [245].